Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

Annals of Oncology

Volumn 7, Issue 7, 1996, Pages 687-693

  Gehl, J ^a   Boesgaard, M ^a   Paaske, T ^b   Vittrup Jensen, B ^a   Dombernowsky, P ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Advanced breast cancer; Cardiotoxicity; Doxorubicin; Paclitaxel

Indexed keywords

CIMETIDINE; CLEMASTINE; DOXORUBICIN; PACLITAXEL; PREDNISOLONE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0029786845     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010717     Document Type: Article

References (29)

1. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: A comparison of their charateristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197-228.
2. Henderson IC, Canellos GP. Cancer of the breast. The past decade. N Engl J Med 1980; 302: 78-90.
3. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44: 17-28.
4. Parker SL, Tong T, Bolden S et al. Cancer statistics 1996. CA Cancer J Clin 1996; 46: 5-27.
5. Seidman AD. The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1995; 1: 247-56.
6. Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169-75.
7. Dombernowsky P, Gehl J, Boesgaard M et al. Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 1996; 23: 13-8.
8. Fisherman JS, McCabe M, Noone M et al. Phase I study of taxol, doxorubicin plus granulocyte colony stimulating factor in patients with metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 189-94.
9. Holmes FA, Valero V, Walters RS et al. The MD Anderson Cancer Center experience with taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 161-9.
10. Sledge GW, Robert N, Sparano JA et al. Paclitaxel (taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Oncology Group Experience. Semin Oncol 1994; 21: 15-8.
11. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
12. Brynjolf I, Kelbœk H, Munck O et al. Right and left ventricular ejection fraction and left ventricular volume changes at rest and during exercise in normal subjects. Eur Heart J 1984; 5: 756-61.
13. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO 1979.
14. Rothberg H, Place CH, Shteir O. Adriamycin (NSC-123127) toxicity: Unusual melanotic reaction. Cancer Chemother Rep 1974; 1: 58: 749-51.
15. Rao SP, Potnis AV, Sobrinho TC et al. Pigmentation of the tongue after treatment with adriamycin. Cancer Treat Rep 1976; 60: 1402-4.
16. The Criteria Committee of the New York Heart Association. Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis (ed 6). Churchill: London, England 1964.
17. Rowinsky EK. Clinical pharmacology of Taxol. Monogr Natl Cancer Inst 1993; 15: 25-37.
18. Perez DJ, Harvey VJ, Robinson BA et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991; 9: 2148-52.
19. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: Lippincott 1993: 1264-332.
20. Bastholt L, Mouridsen HT. How to improve cytotoxic therapy in breast cancer. Acta Oncol 1990; 27: 349-55.
21. Friche E, Jensen PB, Sehested M et al. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 1990; 2: 297-303.
22. Webster L, Linsenmeyer M, Millward M et al. Measurement of cremophor EL following taxol: Plasma levels sufficient to reverse drug exlusion by the multidrug-resistant phenotype. J Natl Cancer Inst 1993; 85: 1685-90.
23. Woodcock DM, Jefferson S, Linsenmeyer ME et al. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water insoluble vitamins and drugs. Cancer Res 1990; 50: 4199-203.
24. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
25. Praga C, Beretta G, Vigo P et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-34.
26. Munzone E, Gianni L, Capri G et al. Cardiac function in breast cancer patients (pts) given paclitaxel (P) by 3-H infusion and previous or concomitant doxorubicin (D). Proc Am Soc Clin Oncol 1995; 14: 128.
27. Holmes FA, Newman RA, Madden T et al. Schedule dependent pharmacokinetics (PK) in a phase I trial of taxol (T) and doxorubicin (D) as initial chemotherapy for metastatic breast cancer. Ann Oncol 1994; 5 (Suppl 5): 197.
28. Berg SL, Cowan KH, Balis FM et al. Pharmacokinetics of taxol and doxorubcin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994; 86(2): 143-5.
29. Gianni L, Locatelli A, Vigano L et al. Order of administration and pharmacokinetics of paclitaxel (P) by 3 H infusion and doxorubicin (D) by i.v. bolus. Proc Am Soc Clin Oncol 1995; 14: 169 (Abstr).